Acadian Asset Management LLC Invests $3.20 Million in Horizon Pharma PLC (HZNP)

Acadian Asset Management LLC acquired a new position in shares of Horizon Pharma PLC (NASDAQ:HZNP) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 163,448 shares of the biopharmaceutical company’s stock, valued at approximately $3,201,000. Acadian Asset Management LLC owned 0.10% of Horizon Pharma at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. First Quadrant L P CA lifted its holdings in shares of Horizon Pharma by 189.1% during the 3rd quarter. First Quadrant L P CA now owns 6,117 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 4,001 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Horizon Pharma by 74.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock worth $128,000 after acquiring an additional 3,877 shares during the period. Quantitative Systematic Strategies LLC purchased a new position in shares of Horizon Pharma during the 2nd quarter worth about $172,000. Strs Ohio lifted its holdings in shares of Horizon Pharma by 74.2% during the 2nd quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 4,600 shares during the period. Finally, Inspirion Wealth Advisors LLC purchased a new position in shares of Horizon Pharma during the 2nd quarter worth about $207,000. Institutional investors and hedge funds own 87.24% of the company’s stock.

HZNP has been the topic of several recent analyst reports. Jefferies Financial Group increased their price objective on shares of Horizon Pharma from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, August 9th. Cowen reiterated a “buy” rating and set a $25.00 price objective on shares of Horizon Pharma in a report on Thursday, August 9th. Piper Jaffray Companies reiterated a “buy” rating and set a $25.00 price objective on shares of Horizon Pharma in a report on Thursday, August 9th. Mizuho reiterated a “buy” rating and set a $18.00 price objective on shares of Horizon Pharma in a report on Wednesday, August 8th. Finally, Cantor Fitzgerald set a $21.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a report on Wednesday, August 8th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Horizon Pharma presently has a consensus rating of “Buy” and a consensus target price of $23.58.

In related news, EVP Geoffrey M. Curtis sold 9,904 shares of the stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $20.63, for a total transaction of $204,319.52. Following the completion of the sale, the executive vice president now owns 28,767 shares of the company’s stock, valued at approximately $593,463.21. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.90% of the stock is currently owned by corporate insiders.

HZNP opened at $22.29 on Friday. The company has a market cap of $3.22 billion, a P/E ratio of 18.89, a price-to-earnings-growth ratio of 1.23 and a beta of 1.29. Horizon Pharma PLC has a 1 year low of $12.55 and a 1 year high of $23.38. The company has a debt-to-equity ratio of 2.19, a current ratio of 1.70 and a quick ratio of 1.63.

Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.15. The firm had revenue of $325.30 million during the quarter, compared to the consensus estimate of $311.84 million. Horizon Pharma had a negative net margin of 28.02% and a positive return on equity of 19.05%. The company’s revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.26 EPS. On average, analysts expect that Horizon Pharma PLC will post 1.34 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/11/10/acadian-asset-management-llc-invests-3-20-million-in-horizon-pharma-plc-hznp.html.

Horizon Pharma Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Read More: Call Option

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply